67 related articles for article (PubMed ID: 3100612)
1. Ceftazidime, a broad spectrum cephalosporin with activity against Ps. aeruginosa.
O'Callaghan H
J Hyg Epidemiol Microbiol Immunol; 1986; 30(4):449-53. PubMed ID: 3100612
[TBL] [Abstract][Full Text] [Related]
2. In vitro properties of ceftazidime, a highly active broad-spectrum cephalosporin with antipseudomonal activity.
Harper PB
Clin Ther; 1984; 6(4):411-24. PubMed ID: 6432324
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of ceftazidime and four other cephalosporins against gram-negative bacteria and their sensitivity to beta-lactamases.
Galante D; Esposito S; Barba D; Pennucci C; Limauro D; Scioli C
Chemioterapia; 1984 Aug; 3(4):250-4. PubMed ID: 6398123
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
6. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins.
Smith BR
Clin Pharm; 1984; 3(4):373-85. PubMed ID: 6380902
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Pfaller MA; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of drug resistance spectrum and its mechanism in 1017 clinical bacterial isolates].
Geng SN; Rui YY; Wang Q; Mou CH; Zhou XH; Zhang J
Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1529-32, 1545. PubMed ID: 16361155
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial profile of ceftazidime: the situation in three larger hospitals in Prague between 1981 and 1983.
Hejzlar M; Sedmidubský V; Procházková A; Dvorský V; Stastná L; Paroubek M; Kotasová M; Puchmayerová M; Silarová J; Gleichová L
J Hyg Epidemiol Microbiol Immunol; 1984; 29(3):311-5. PubMed ID: 6443365
[TBL] [Abstract][Full Text] [Related]
11. [Monitoring of bacteria resistance in burn patients].
Zhang M; Xu X; Liao P
Zhonghua Wai Ke Za Zhi; 1999 May; 37(5):278-81. PubMed ID: 11829839
[TBL] [Abstract][Full Text] [Related]
12. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
Buijs J; Dofferhoff AS; Mouton JW; Wagenvoort JH; van der Meer JW
Clin Microbiol Infect; 2008 Apr; 14(4):344-9. PubMed ID: 18261128
[TBL] [Abstract][Full Text] [Related]
13. [Effect of inoculum size on sensitivity and specificity of the double-disk synergy test for the detection of wide-spectrum beta-lactamases].
Bedenić B; Boras A
Lijec Vjesn; 2001; 123(11-12):293-6. PubMed ID: 11930754
[TBL] [Abstract][Full Text] [Related]
14. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of sulperazon against recent isolates of ceftazidime-resistant bacteria.
Lim VK; Halijah MY
Med J Malaysia; 2001 Sep; 56(3):365-9. PubMed ID: 11732084
[TBL] [Abstract][Full Text] [Related]
16. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
Zarakolu P; Hasçelik G; Unal S
Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
[TBL] [Abstract][Full Text] [Related]
17. [Sensitivity of Pseudomonas aeruginosa and Klebsiella spp. to ceftazidime. Current status in France].
Thabaut A; Acar J; Arlet G; Berardi-Grassias L; Bergogne-Bérézin E; Brun Y; Buisson Y; Chabanon G; Cluzel R; Courtieu A
Presse Med; 1988 Oct; 17(37):1895-9. PubMed ID: 2973580
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the in vitro activity of ceftazidime: in culture, in serum and in combination with granulocytes].
Daschner FD; Bassler M; Grundau D; Dieterle L; Just HM
Immun Infekt; 1983 Nov; 11(6):221-8. PubMed ID: 6439624
[TBL] [Abstract][Full Text] [Related]
19. In-vitro and in-vivo antibacterial activities of E1040, a new cephalosporin with potent antipseudomonal activity.
Hiruma R; Otsuki M; Tashima M; Obana Y; Nishino T
J Antimicrob Chemother; 1990 Dec; 26(6):769-81. PubMed ID: 2127928
[TBL] [Abstract][Full Text] [Related]
20. L-658,310, a new injectable cephalosporin. I. In vitro antibacterial properties.
Weissberger BA; Abruzzo GK; Fromtling RA; Gill C; Ponticas S; Valiant ME; Shungu DL; Gadebusch HH
J Antibiot (Tokyo); 1989 May; 42(5):795-806. PubMed ID: 2498277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
